X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4043) 4043
Newsletter (695) 695
Publication (352) 352
Book Review (90) 90
Magazine Article (26) 26
Book Chapter (23) 23
Book / eBook (16) 16
Dissertation (7) 7
Newspaper Article (7) 7
Conference Proceeding (4) 4
Data Set (4) 4
Reference (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3291) 3291
pharmacology & pharmacy (2174) 2174
index medicus (1814) 1814
cytochrome p-450 (1808) 1808
cytochrome p-450 enzyme system - metabolism (1238) 1238
male (1195) 1195
female (1096) 1096
metabolism (1096) 1096
drug interactions (973) 973
research (869) 869
pharmacokinetics (862) 862
animals (841) 841
adult (810) 810
cytochrome p-450 cyp2d6 - metabolism (778) 778
cytochrome p450 (757) 757
cytochrome p-450 cyp2d6 - genetics (725) 725
cyp2d6 (710) 710
cytochrome p-450 enzyme inhibitors (691) 691
physiological aspects (649) 649
middle aged (633) 633
enzymes (621) 621
genotype (619) 619
pharmacogenetics (618) 618
microsomes, liver - enzymology (611) 611
in-vitro (584) 584
enzyme inhibitors - pharmacology (545) 545
toxicology (527) 527
cytochrome p-450 cyp2d6 inhibitors (505) 505
microsomes, liver - metabolism (492) 492
human liver-microsomes (491) 491
cytochrome p-450 enzyme system - genetics (471) 471
microsomes, liver - drug effects (437) 437
kinetics (431) 431
genetic aspects (416) 416
inhibition (415) 415
aged (410) 410
metabolites (400) 400
drugs (390) 390
rats (369) 369
hydroxylation (361) 361
cytochrome p-450 cyp3a (356) 356
analysis (341) 341
phenotype (339) 339
drug metabolism (337) 337
reports (337) 337
polymorphism, genetic (332) 332
dose-response relationship, drug (302) 302
biotransformation (299) 299
polymorphism (298) 298
pharmacology (297) 297
cytochrome (293) 293
in vitro techniques (291) 291
liver (290) 290
biochemistry & molecular biology (284) 284
tamoxifen (279) 279
health aspects (272) 272
isoenzymes - metabolism (272) 272
cancer (267) 267
psychiatry (266) 266
cyp3a4 (265) 265
genetic polymorphisms (264) 264
care and treatment (262) 262
cytochrome p-450 cyp2c19 (259) 259
cytochrome p-450 cyp3a - metabolism (254) 254
drug therapy (254) 254
antidepressants (241) 241
universities and colleges (238) 238
chromatography, high pressure liquid (234) 234
mixed function oxygenases - metabolism (231) 231
oxidation (230) 230
aryl hydrocarbon hydroxylases - genetics (218) 218
oncology (216) 216
breast cancer (214) 214
expression (214) 214
drug-interactions (207) 207
recombinant proteins - metabolism (204) 204
young adult (200) 200
adolescent (199) 199
area under curve (199) 199
substrate specificity (199) 199
alleles (198) 198
drug-drug interactions (194) 194
cytochrome p-450 cyp2d6 (192) 192
drug-metabolism (192) 192
mixed function oxygenases - antagonists & inhibitors (192) 192
chemistry, medicinal (191) 191
microsomes (191) 191
aryl hydrocarbon hydroxylases - metabolism (190) 190
pharmaceutical preparations - metabolism (190) 190
breast neoplasms - drug therapy (189) 189
cytochrome p-450 cyp2c9 (187) 187
medicine (187) 187
identification (184) 184
isoenzymes - antagonists & inhibitors (176) 176
cyp2c19 (175) 175
treatment outcome (174) 174
p-glycoprotein (171) 171
inhibitors (168) 168
liver - enzymology (167) 167
mass spectrometry (167) 167
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4768) 4768
Spanish (11) 11
German (9) 9
Japanese (7) 7
French (6) 6
Chinese (5) 5
Polish (4) 4
Dutch (2) 2
Danish (1) 1
Italian (1) 1
Norwegian (1) 1
Russian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 02/2015, Volume 43, Issue 2, pp. 182 - 189
Evaluation of drug-drug interaction (DDI) involving circulating inhibitory metabolites of perpetrator drugs has recently drawn more attention from regulatory... 
IN-VITRO | WARFARIN | KINETICS | HUMANS | PHARMACOLOGY & PHARMACY | PLASMA-PROTEIN BINDING | DESETHYLAMIODARONE | DISCOVERY | DIALYSIS | Cytochrome P-450 CYP2D6 Inhibitors - chemistry | Liver - enzymology | Cytochrome P-450 CYP2D6 Inhibitors - metabolism | Expert Systems | Humans | Middle Aged | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Cytochrome P-450 CYP2C9 Inhibitors - chemistry | Amiodarone - blood | Anti-Arrhythmia Agents - metabolism | Amiodarone - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Drug Interactions | Liver - drug effects | Amiodarone - pharmacokinetics | Computer Simulation | Cytochrome P-450 CYP3A Inhibitors - chemistry | Cytochrome P-450 CYP2C9 Inhibitors - metabolism | Adult | Female | Cytochrome P-450 CYP2C9 Inhibitors - blood | Reproducibility of Results | Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - blood | Administration, Oral | Liver - metabolism | Amiodarone - antagonists & inhibitors | Anti-Arrhythmia Agents - chemistry | Anti-Arrhythmia Agents - pharmacokinetics | Anti-Arrhythmia Agents - administration & dosage | Amiodarone - analogs & derivatives | Amiodarone - metabolism | Cytochrome P-450 CYP3A Inhibitors - metabolism | Models, Biological | Biotransformation - drug effects | Cytochrome P-450 CYP2D6 Inhibitors - blood | Infusions, Intravenous | Cytochrome P-450 CYP2C9 Inhibitors - pharmacokinetics
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2017, Volume 60, Issue 15, pp. 6678 - 6692
Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers.... 
TARGET | CHEMISTRY, MEDICINAL | PATHWAY | MECHANISMS | BETA-CATENIN | WNT | CANCER | Acyltransferases - antagonists & inhibitors | Maleimides - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Microsomes, Liver - metabolism | Maleimides - pharmacology | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Maleimides - pharmacokinetics | Cytochrome P-450 CYP1A2 Inhibitors - pharmacokinetics | Maleimides - chemical synthesis | HEK293 Cells | Pyridazines - administration & dosage | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP2D6 Inhibitors - pharmacology | Wnt Signaling Pathway | Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Rats | Cytochrome P-450 CYP1A2 Inhibitors - chemical synthesis | Cytochrome P-450 CYP2D6 Inhibitors - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - chemical synthesis | Xenograft Model Antitumor Assays | Animals | Cytochrome P-450 CYP1A2 Inhibitors - pharmacology | Cytochrome P-450 CYP2D6 Inhibitors - chemical synthesis | High-Throughput Screening Assays | Membrane Proteins - antagonists & inhibitors | Mice, Nude | Cytochrome P-450 CYP1A2 Inhibitors - administration & dosage | Cell Line, Tumor | Pyridazines - pharmacokinetics | Mice, Inbred BALB C
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 01/2005, Volume 97, Issue 1, pp. 30 - 39
Background: The efficacy of tamoxifen therapy for the treatment of breast cancer varies widely among individuals. Plasma concentrations of the active tamoxifen... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | TRIAL | IN-VITRO | PLASMA | ONCOLOGY | JAPANESE POPULATION | ALLELE FREQUENCY | PAROXETINE | POSTMENOPAUSAL WOMEN | HOT FLASHES | CYTOCHROME-P450 2D6 | Cytochrome P-450 CYP2C9 | Cytochrome P-450 CYP2D6 Inhibitors | Prospective Studies | Cytochrome P-450 CYP3A | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Antidepressive Agents, Second-Generation - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Agents, Hormonal - metabolism | Breast Neoplasms - metabolism | Breast Neoplasms - enzymology | Cyclohexanols - metabolism | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Serotonin Uptake Inhibitors - metabolism | Tamoxifen - metabolism | Cytochrome P-450 CYP2D6 - genetics | Drug Administration Schedule | Enzyme Inhibitors - metabolism | Estrogen Receptor Modulators - administration & dosage | Antineoplastic Agents, Hormonal - administration & dosage | Tamoxifen - blood | Genotype | Arylsulfotransferase - genetics | Estrogen Receptor Modulators - blood | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - blood | Venlafaxine Hydrochloride | Serotonin Uptake Inhibitors - administration & dosage | Cytochrome P-450 Enzyme System - genetics | Aged | Estrogen Receptor Modulators - metabolism | Antidepressive Agents, Second-Generation - metabolism | Breast cancer | Dosage and administration | Drug therapy | Tamoxifen | Antidepressants
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 06/2014, Volume 95, Issue 6, pp. 653 - 662
Journal Article
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 06/2010, Volume 160, Issue 4, pp. 919 - 930
Background and purpose:  The major drug-metabolizing enzymes for the oxidation of oxycodone are CYP2D6 and CYP3A. A high interindividual variability in the... 
CYP3A | drug-drug interactions | CYP2D6 | pharmacodynamics | oxycodone | oxymorphone | experimental pain | genetic polymorphism | drug–drug interactions | Pharmacodynamics | Oxycodone | Genetic polymorphism | Experimental pain | Drug-drug interactions | Oxymorphone | MORPHINE | CONTROLLED-RELEASE OXYCODONE | P-GLYCOPROTEIN | PAIN | METABOLISM | PHARMACOKINETICS | IN-VIVO | ORAL OXYCODONE | PHARMACOLOGY & PHARMACY | CODEINE | RECEPTOR-BINDING | Cytochrome P-450 CYP2D6 Inhibitors | Humans | Middle Aged | Analgesics, Opioid - pharmacology | Male | Young Adult | Analgesics, Opioid - adverse effects | Drug Interactions | Pain Threshold - drug effects | Adult | Oxycodone - adverse effects | Metabolic Detoxication, Phase I - genetics | Oxymorphone - blood | Cytochrome P-450 CYP2D6 - genetics | Oxycodone - therapeutic use | Reflex, Pupillary - drug effects | Oxycodone - pharmacology | Double-Blind Method | Enzyme Inhibitors - pharmacology | Analgesics, Opioid - therapeutic use | Genotype | Psychomotor Performance - drug effects | Polymorphism, Genetic | Cross-Over Studies | Oxycodone - pharmacokinetics | Phenotype | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP3A - metabolism | Analgesics, Opioid - pharmacokinetics | Cytochrome P-450 CYP2D6 - metabolism | Drug therapy | Enzymes | Pain | Pain perception | Ketoconazole | Toxicity | Cytochrome P450 | Gene polymorphism | Electrical stimuli | Side effects | Analgesics | Metabolites | Quinidine | Drug interaction | Oxidation | Pharmacokinetics | CYP2D6 protein | Research Papers
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 11/2005, Volume 33, Issue 11, pp. 1723 - 1728
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2007, Volume 101, Issue 1, pp. 113 - 121
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 06/2010, Volume 160, Issue 4, pp. 907 - 918
Journal Article